hVIVO plc (LON:HVO - Get Free Report)'s share price fell 6.8% during mid-day trading on Thursday . The company traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). 2,518,262 shares changed hands during trading, a decline of 26% from the average session volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.25).
hVIVO Trading Down 6.8 %
The stock's fifty day simple moving average is GBX 23.39 and its 200-day simple moving average is GBX 26.71. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The firm has a market cap of £129.95 million, a PE ratio of 636.67 and a beta of 0.97.
hVIVO Company Profile
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Further Reading
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
